Do analysts recommend ELYM or XNCR?

Xencor has a consensus target price of $24.86, suggesting a potential upside of 6.50%. Given Xencor's stronger consensus rating and higher possible upside, analysts plainly believe Xencor is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Xencor 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.44

Do analysts prefer ELYM or TRAX?

First Tracks Biotherapeutics has a consensus price target of $60.50, indicating a potential upside of 37.38%. Given First Tracks Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe First Tracks Biotherapeutics is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 First Tracks Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70

Which has preferable valuation and earnings, ELYM or TRAX?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than First Tracks Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A First Tracks Biotherapeutics N/A N/A N/A -$1.84 N/A

Is ELYM or TRAX more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Eliem Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% First Tracks Biotherapeutics N/A N/A N/A

Do analysts prefer BCAX or ELYM?

Bicara Therapeutics presently has a consensus target price of $32.73, indicating a potential upside of 34.79%. Given Bicara Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Bicara Therapeutics is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicara Therapeutics 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.73 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, BCAX or ELYM?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bicara Therapeutics N/A N/A -$137.95M -$2.78 N/A Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A

Is BCAX or ELYM more profitable?

Bicara Therapeutics' return on equity of -41.49% beat Eliem Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Bicara Therapeutics N/A -41.49% -38.59% Eliem Therapeutics N/A -47.03% -45.97%

Do analysts prefer ELYM or MAZE?

Maze Therapeutics has a consensus price target of $66.00, suggesting a potential upside of 142.83%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Maze Therapeutics is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Maze Therapeutics 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.00

Is ELYM or MAZE more profitable?

Maze Therapeutics' return on equity of -34.94% beat Eliem Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% Maze Therapeutics N/A -34.94% -30.18%

Do analysts recommend VIR or ELYM?

Vir Biotechnology presently has a consensus target price of $20.63, suggesting a potential upside of 123.21%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, equities research analysts clearly believe Vir Biotechnology is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vir Biotechnology 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Eliem Therapeutics (ELYM) Competitors

$14.73 +0.34 (+2.36%)

As of 08/13/2026

Compare

ELYM vs. XNCR, TRAX, BCAX, MAZE, and VIR

Should you buy Eliem Therapeutics stock or one of its competitors? Eliem Therapeutics's main competitors and comparable companies include Xencor (XNCR), First Tracks Biotherapeutics (TRAX), Bicara Therapeutics (BCAX), Maze Therapeutics (MAZE), and Vir Biotechnology (VIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Eliem Therapeutics compare to Xencor?

Eliem Therapeutics (NASDAQ:ELYM) and Xencor (NASDAQ:XNCR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

69.8% of Eliem Therapeutics shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by company insiders. Comparatively, 5.1% of Xencor shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Eliem Therapeutics has higher earnings, but lower revenue than Xencor. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Xencor	$104.97M	16.53	-$91.92M	-$2.17	N/A

Eliem Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Xencor	-155.59%	-28.66%	-20.38%

Xencor has a consensus target price of $24.86, suggesting a potential upside of 6.50%. Given Xencor's stronger consensus rating and higher possible upside, analysts plainly believe Xencor is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Xencor	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market. Comparatively, Xencor has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

In the previous week, Xencor had 8 more articles in the media than Eliem Therapeutics. MarketBeat recorded 8 mentions for Xencor and 0 mentions for Eliem Therapeutics. Xencor's average media sentiment score of 0.41 beat Eliem Therapeutics' score of 0.00 indicating that Xencor is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Xencor	Neutral

Summary

Xencor beats Eliem Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Eliem Therapeutics compare to First Tracks Biotherapeutics?

Eliem Therapeutics (NASDAQ:ELYM) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

First Tracks Biotherapeutics' return on equity of 0.00% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
First Tracks Biotherapeutics	N/A	N/A	N/A

Eliem Therapeutics is trading at a lower price-to-earnings ratio than First Tracks Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A

69.8% of Eliem Therapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, First Tracks Biotherapeutics had 9 more articles in the media than Eliem Therapeutics. MarketBeat recorded 9 mentions for First Tracks Biotherapeutics and 0 mentions for Eliem Therapeutics. First Tracks Biotherapeutics' average media sentiment score of 0.29 beat Eliem Therapeutics' score of 0.00 indicating that First Tracks Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
First Tracks Biotherapeutics	Neutral

First Tracks Biotherapeutics has a consensus price target of $60.50, indicating a potential upside of 37.38%. Given First Tracks Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe First Tracks Biotherapeutics is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Summary

First Tracks Biotherapeutics beats Eliem Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Eliem Therapeutics compare to Bicara Therapeutics?

Bicara Therapeutics (NASDAQ:BCAX) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Bicara Therapeutics has a beta of -0.75, indicating that its share price is 175% less volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the broader market.

In the previous week, Bicara Therapeutics had 29 more articles in the media than Eliem Therapeutics. MarketBeat recorded 29 mentions for Bicara Therapeutics and 0 mentions for Eliem Therapeutics. Bicara Therapeutics' average media sentiment score of 0.37 beat Eliem Therapeutics' score of 0.00 indicating that Bicara Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Bicara Therapeutics	Neutral
Eliem Therapeutics	Neutral

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Bicara Therapeutics presently has a consensus target price of $32.73, indicating a potential upside of 34.79%. Given Bicara Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Bicara Therapeutics is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

69.8% of Eliem Therapeutics shares are held by institutional investors. 13.8% of Bicara Therapeutics shares are held by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bicara Therapeutics' return on equity of -41.49% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-41.49%	-38.59%
Eliem Therapeutics	N/A	-47.03%	-45.97%

Summary

Bicara Therapeutics beats Eliem Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Eliem Therapeutics compare to Maze Therapeutics?

Eliem Therapeutics (NASDAQ:ELYM) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market.

Eliem Therapeutics has higher earnings, but lower revenue than Maze Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
Maze Therapeutics	$167.50M	9.01	-$131.12M	-$2.53	N/A

Maze Therapeutics' return on equity of -34.94% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
Maze Therapeutics	N/A	-34.94%	-30.18%

69.8% of Eliem Therapeutics shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by insiders. Comparatively, 5.3% of Maze Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Maze Therapeutics had 22 more articles in the media than Eliem Therapeutics. MarketBeat recorded 22 mentions for Maze Therapeutics and 0 mentions for Eliem Therapeutics. Maze Therapeutics' average media sentiment score of 0.69 beat Eliem Therapeutics' score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
Maze Therapeutics	Positive

Maze Therapeutics has a consensus price target of $66.00, suggesting a potential upside of 142.83%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Maze Therapeutics is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Maze Therapeutics beats Eliem Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Eliem Therapeutics compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Eliem Therapeutics has lower revenue, but higher earnings than Vir Biotechnology. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	22.81	-$437.99M	-$1.86	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Vir Biotechnology has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market.

Vir Biotechnology presently has a consensus target price of $20.63, suggesting a potential upside of 123.21%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, equities research analysts clearly believe Vir Biotechnology is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Eliem Therapeutics has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -29.99% beat Eliem Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-29.99%	-23.62%
Eliem Therapeutics	N/A	-47.03%	-45.97%

In the previous week, Vir Biotechnology had 20 more articles in the media than Eliem Therapeutics. MarketBeat recorded 20 mentions for Vir Biotechnology and 0 mentions for Eliem Therapeutics. Eliem Therapeutics' average media sentiment score of 0.00 beat Vir Biotechnology's score of -0.12 indicating that Eliem Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Vir Biotechnology	Neutral
Eliem Therapeutics	Neutral

65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Vir Biotechnology beats Eliem Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Eliem Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELYM vs. The Competition

Export

Metric	Eliem Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$438.25M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-27.79	10.67	269.06	25.28
Price / Sales	N/A	1,294.08	602.43	91.76
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	3.78	16.78	12.91	6.24
Net Income	-$35.12M	-$13.32M	$3.45B	$347.60M
7 Day Performance	5.21%	1.74%	1.12%	1.07%
1 Month Performance	11.51%	1.60%	1.79%	1.03%
1 Year Performance	803.68%	56.43%	67.69%	20.77%

Eliem Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELYM Eliem Therapeutics	N/A	$14.73 +2.4%	N/A	+793.8%	$438.25M	N/A	N/A	9	High Trading Volume
XNCR Xencor	1.3197 of 5 stars	$23.18 +4.9%	$24.86 +7.2%	+197.8%	$1.64B	$125.58M	N/A	280
TRAX First Tracks Biotherapeutics	3.6221 of 5 stars	$46.13 -1.3%	$50.38 +9.2%	N/A	$1.63B	N/A	N/A	N/A	News Coverage Earnings Report Analyst Forecast
BCAX Bicara Therapeutics	2.0965 of 5 stars	$24.63 +3.7%	$32.73 +32.9%	+108.6%	$1.56B	N/A	N/A	32	News Coverage Earnings Report Analyst Forecast Insider Trade Gap Down
MAZE Maze Therapeutics	2.0315 of 5 stars	$27.53 +0.8%	$66.00 +139.7%	+103.5%	$1.51B	$167.50M	N/A	121	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELYM) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eliem Therapeutics (ELYM) Competitors

ELYM vs. XNCR, TRAX, BCAX, MAZE, and VIR

How does Eliem Therapeutics compare to Xencor?

Summary

How does Eliem Therapeutics compare to First Tracks Biotherapeutics?

Summary

How does Eliem Therapeutics compare to Bicara Therapeutics?

Summary

How does Eliem Therapeutics compare to Maze Therapeutics?

Summary

How does Eliem Therapeutics compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELYM vs. The Competition

Eliem Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eliem Therapeutics (ELYM) Competitors

ELYM vs. XNCR, TRAX, BCAX, MAZE, and VIR

How does Eliem Therapeutics compare to Xencor?

Do insiders and institutionals believe in ELYM or XNCR?

Which has higher earnings and valuation, ELYM or XNCR?

Is ELYM or XNCR more profitable?

Do analysts recommend ELYM or XNCR?

Which has more volatility and risk, ELYM or XNCR?

Does the media prefer ELYM or XNCR?

Summary

How does Eliem Therapeutics compare to First Tracks Biotherapeutics?

Is ELYM or TRAX more profitable?

Which has preferable valuation and earnings, ELYM or TRAX?

Do institutionals & insiders believe in ELYM or TRAX?

Does the media refer more to ELYM or TRAX?

Do analysts prefer ELYM or TRAX?

Summary

How does Eliem Therapeutics compare to Bicara Therapeutics?

Which has more volatility & risk, BCAX or ELYM?

Does the media refer more to BCAX or ELYM?

Which has higher valuation & earnings, BCAX or ELYM?

Do analysts prefer BCAX or ELYM?

Do institutionals and insiders have more ownership in BCAX or ELYM?

Is BCAX or ELYM more profitable?

Summary

How does Eliem Therapeutics compare to Maze Therapeutics?

Which has more risk and volatility, ELYM or MAZE?

Which has better earnings and valuation, ELYM or MAZE?

Is ELYM or MAZE more profitable?

Do insiders and institutionals hold more shares of ELYM or MAZE?

Does the media prefer ELYM or MAZE?

Do analysts prefer ELYM or MAZE?

Summary

How does Eliem Therapeutics compare to Vir Biotechnology?

Which has preferable earnings and valuation, VIR or ELYM?

Which has more volatility & risk, VIR or ELYM?

Do analysts recommend VIR or ELYM?

Is VIR or ELYM more profitable?

Does the media favor VIR or ELYM?

Do institutionals & insiders hold more shares of VIR or ELYM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELYM vs. The Competition

Eliem Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools